Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Carmell Therapeutics Corporation (CTCXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/07/2025: CTCXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/07/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 9556 | Beta - | 52 Weeks Range 0.02 - 0.15 | Updated Date 02/26/2025 |
52 Weeks Range 0.02 - 0.15 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Carmell Therapeutics Corporation
Company Overview
History and Background
Carmell Therapeutics Corporation is a bio-pharmaceutical company focused on the development and commercialization of Plasma-based Bio-materials (PBMs) for bone and wound healing. It was founded to address limitations in existing regenerative medicine approaches.
Core Business Areas
- Bone Healing: Developing PBMs to accelerate and improve bone fracture repair and spinal fusion procedures.
- Wound Healing: Developing PBMs to promote faster and more complete healing of chronic wounds, such as diabetic ulcers.
Leadership and Structure
Carmell Therapeutics has a management team led by Randy Hubbell (CEO). The organizational structure includes departments focused on research and development, clinical trials, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Bone Healing Products (PBMs): Carmell's core focus is on bone healing products derived from platelet-rich plasma. These PBMs aim to improve bone fracture repair and spinal fusion outcomes. Currently they have not received FDA approval. Competitors include Medtronic (MDT), Stryker (SYK), and Johnson & Johnson (JNJ) in the broader bone graft market.
- Wound Healing Products (PBMs): Carmell is also developing PBMs for wound healing, targeting chronic wounds like diabetic ulcers. Currently they have not received FDA approval. Competitors include Smith & Nephew (SNN), Integra LifeSciences (IART), and Organogenesis (ORGO) in the advanced wound care market.
Market Dynamics
Industry Overview
The regenerative medicine market is experiencing significant growth, driven by an aging population and increasing demand for advanced therapies. Key trends include personalized medicine, biologics, and minimally invasive procedures.
Positioning
Carmell Therapeutics aims to differentiate itself through its PBM technology, which is designed to enhance the body's natural healing processes. Its competitive advantage lies in its proprietary technology platform and focus on specific applications within bone and wound healing.
Total Addressable Market (TAM)
The total addressable market for bone and wound healing is estimated to be billions of dollars. Carmell is positioned to capture a share of this market with its PBM technology, contingent upon regulatory approvals and successful commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary PBM technology platform
- Focus on large and growing markets (bone and wound healing)
- Potential for improved clinical outcomes compared to existing therapies
Weaknesses
- Dependence on regulatory approvals (FDA)
- Limited commercialization experience
- High capital requirements for clinical trials and manufacturing
Opportunities
- Partnerships with leading healthcare providers
- Expansion into new applications for PBM technology
- Acquisition by a larger medical device company
Threats
- Competition from established players in the bone and wound healing markets
- Failure to obtain regulatory approvals
- Technological advancements that render PBM technology obsolete
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Stryker (SYK)
- Johnson & Johnson (JNJ)
- Smith & Nephew (SNN)
- Integra LifeSciences (IART)
- Organogenesis (ORGO)
Competitive Landscape
Carmell Therapeutics faces intense competition from established medical device companies. Its success depends on demonstrating the clinical and economic value of its PBM technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization of PBM products.
Recent Initiatives: Recent initiatives include completing clinical trials and preparing for regulatory submissions.
Summary
Carmell Therapeutics is a development-stage bio-pharmaceutical company with innovative PBM technology, which it hopes to commercialize. Its success is heavily reliant on obtaining regulatory approvals for bone and wound healing. They face strong competition and high capital needs. Significant opportunities exist for growth through strategic partnerships.
Similar Companies
IART
Integra LifeSciences Holdings
IART
Integra LifeSciences Holdings
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MDT
Medtronic PLC
MDT
Medtronic PLC
ORGO
Organogenesis Holdings Inc
ORGO
Organogenesis Holdings Inc
SNN
Smith & Nephew SNATS Inc
SNN
Smith & Nephew SNATS Inc
SYK
Stryker Corporation
SYK
Stryker Corporation
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Carmell Therapeutics Corporation
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-07-17 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website |
Full time employees 9 | Website | ||
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.